References

The Migraine And Headache Program

Natural Migraine Relief and Treatment

Get Instant Access

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453-468.

2. Bladin CF, Alexandrov AV, Bellavance A et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57:1617-1622.

3. Vespa PM, O'Phelan K, Shah M et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology 2003; 60:1441-1446.

4. Arboix A, Garcia-Eroles L, Massons JB et al. Predictive factors of early seizures after acute cerebrovascular disease. Stroke 1997; 28:1590-1594.

5. Ferracci F, Moretto G, Gentile M et al. Can seizures be the only manifestation of transient ischemic attacks? A report of four cases. Neurol Sci 2000; 21:303-306.

6. Giroud M, Gras P, Fayolle H et al. Early seizures after acute stroke: a study of 1,640 cases. Epilepsia 1994; 35:959-964.

7. Williams AJ, Tortella FC, Lu XM et al. Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia. J Pharmacol Exp Ther 2004; 311:220-227.

8. Berger AR, Lipton RB, Lesser ML et al. Early seizures following intracerebral hemorrhage: implications for therapy. Neurology 1988; 38:1363-1365.

9. Naidech AM, Kreiter KT, Janjua N et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005; 36:583-587.

10. Goldstein LB. Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Neurology 1995; 45:865-871.

11. Gupta SR, Naheedy MH, Elias D et al. Postinfarction seizures. A clinical study. Stroke 1988; 19:1477-1481.

12. Alvarez-Sabin J, Montaner J, Padro L et al. Gabapentin in late-onset poststroke seizures. Neurology 2002; 59:1991-1993.

13. Rowan AJ, Ramsay RE, Collins JF et al; VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64:1868-1873.

14. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.

15. Man-Son-Hing M, Nichol G, Lau A et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159:677-685.

16. Galimberti CA, Marchioni E, Barzizza F et al. Partial epileptic seizures of different origin variably affect cardiac rhythm. Epilepsia 1996; 37:742-747.

17. Rossetti AO, Dworetzky BA, Madsen JR et al. Ictal asystole with convulsive syncope mimicking secondary generalisation: a depth electrode study. J Neurol Neurosurg Psychiatry 2005; 76:885-887.

18. Tigaran S, Rasmussen V, Dam M et al. ECG changes in epilepsy patients. Acta Neurol Scand 1997; 96:72-75.

19. Khan JA, Gowda RM. Novel therapeutics for treatment of long-QT syndrome and torsades de pointes. Int J Cardiol 2004; 95:1-6.

20. Binder L, Trujillo J, Parker D et al. Association of intravenous phenytoin toxicity with demographic, clinical and dosing parameters. Am J Emer Med 1996; 14:398-401.

21. Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 1991; 20:139-142.

22. Adams BD, Buckley NH, Kim JY et al. Fosphenytoin may cause hemodynamically unstable bradydys-rhythmias. J Emerg Med 2006; 30:75-79.

23. Megarbane B, Leprince P, Deye N et al. Extracorporeal life support in a case of acute carbamazepine poisoning with life-threatening refractory myocardial failure. Intensive Care Med 2006; 32:1409-1413.

24. Faisy C, Guerot E, Diehl JL et al. Carbamazepine-associated severe left ventricular dysfunction. J Toxicol Clin Toxicol 2000; 38:339-342.

25. Kasarskis EJ, Kuo CS, Berger R et al. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992; 152:186-191.

26. Timmings PL. Sudden unexpected death in epilepsy: is carbamazepine implicated? Seizure 1998; 7:289-291.

27. Roberts C, French JA. Anticonvulsants in acute medical illness. In: Delanty N (ed.) Seizures: Medical Causes and Management. Totowa, NJ: Humana Press, 2002, pp. 333-356.

28. Hubalewska A, Stompor T, Placzkiewicz E et al. Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal. Nucl Med Rev Cent East Eur 2004; 7:27-30.

29. Strid H, Simren M, Stotzer PO et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 2003; 67:129-137.

30. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984; 9:S18-S26.

31. Randinitis EJ, Posvar EL, Alvey CW et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003; 43:277-283.

32. Browne TR. Renal disorders. In: Ettinger AB, Devinsky O (eds) Managing Epilepsy and Co-existing Disorders. Boston: Butterworth-Heinemann, 2002, pp. 49-62.

33. Munoz R, Espinoza M, Espinoza O et al. Cyclosporine-associated leukoencephalopathy in organ transplant recipients: experience of three clinical cases. Transplant Proc 2006; 38:921-923.

34. Wong R, Beguelin GZ, de Lima M et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122:128-134.

35. Racusen LC, McCrindle BW, Christenson M et al. Cyclosporine lowers seizure threshold in an experimental model of electroshock-induced seizures in Munich-Wistar rats. Life Sci 1990; 46:1021-1026.

36. Wassner SJ, Pennisi AJ, Malekzadeh MH et al. The adverse effect of anticonvulsant therapy on renal allograft survival. A preliminary report. J Pediatr 1976; 88:134-137.

37. Wassner SJ, Malekzadeh MH, Pennisi AJ et al. Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol 1977; 8:293-297.

38. Gallay BJ, de Mattos AM, Norman DJ. Reversible acute renal allograft dysfunction due to gabapentin. Transplantation 2000; 70:208-209.

39. AMNCH Adult Medicines Guide 2006/7: 224-225.

40. Glass GA, Stankiewicz J, Mithoefer A et al. Levetiracetam for seizures after liver transplantation. Neurology 2005; 64:1084-1085.

41. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119:S30-S35.

42. Dong X, Leppik IE, White J et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65:1976-1978.

43. Kuz GM, Manssourian A. Carbamazepine-induced hyponatremia: assessment of risk factors. Ann Pharmacother 2005; 39:1943-1946.

44. Banner W Jr, Johnson DG, Walson PD et al. Effects of single large doses of phenytoin on glucose homeostasis - a preliminary report. J Clin Pharmacol 1982; 22:79-81.

45. Di Gennaro G, Quarato PP, Colazza GB et al. Hypoglycaemia induced by phenytoin treatment for partial status epilepticus. J Neurol Neurosurg Psychiatry 2002; 73:349-350.

46. Manto M, Preiser JC, Vincent JL. Hypoglycemia associated with phenytoin intoxication. J Toxicol Clin Toxicol 1996; 34:205-208.

47. Lavin PJ. Hyperglycemic hemianopia: a reversible complication of non-ketotic hyperglycemia. Neurology 2005; 65:616-619.

48. Gupta MM. Medical emergencies associated with disorders of calcium homeostasis. J Assoc Physicians India 1989; 37:629-631.

49. Ali FE, Al-Bustan MA, Al-Busairi WA et al. Loss of seizure control due to anticonvulsant-induced hypocalcemia. Ann Pharmacother 2004; 38:1002-1005.

50. Crimlisk HL. The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997; 62:319-328.

51. Bylesjo I, Forsgren L, Lithner F et al. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia 1996; 37:230-235.

52. Zadra M, Grandi R, Erli LC et al. Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. Seizure 1998; 7:415-416.

53. Tatum WO 4th, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995; 45:1216-1217.

54. Lambrecht RW, Gildemeister OS, Pepe JA et al. Effects of antidepressants and benzodiazepine-type anxiolytic agents on hepatic porphyrin accumulation in primary cultures of chick embryo liver cells. J Pharmacol Exp Ther 1999; 291:1150-1155.

55. Krijt J, Krijtova H, Sanitrak J. Effect of tiagabine and topiramate on porphyrin metabolism in an in vivo model of porphyria. Pharmacol Toxicol 2001; 89:15-22.

56. Gaida-Hommernick B, Rieck K, Runge U. Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2001; 42:793-795.

57. Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2004; 45:559-560.

58. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol 2005; 28:243-244.

59. Gaynor JW, Jarvik GP, Bernbaum J et al. The relationship of postoperative electrographic seizures to neurodevelopmental outcome at 1 year of age after neonatal and infant cardiac surgery. J Thorac Cardiovasc Surg 2006; 131:181-189.

60. Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (Part II). Anesth Analg 1990; 70:433-444.

61. Voss LJ, Ludbrook G, Grant C et al. Cerebral cortical effects of desflurane in sheep: comparison with isoflurane, sevoflurane and enflurane. Acta Anaesthesiol Scand 2006; 50:313-319.

62. Varelas PN, Mirski MA. Seizures in the adult intensive care unit. J Neurosurg Anasthesiol 2001; 13:163-175.

63. Weinhouse GL, Schwab RJ. Sleep in the critically ill patient. Sleep 2006; 29:707-716.

64. Forsgren L, Bucht G, Eriksson S et al. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996; 37:224-229.

65. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004; 62:S24-S29.

66. AJ Rowan. Epilepsy and seizures in the aged. In: Ettinger AB, Devinsky O (eds) Managing Epilepsy and Co-existing Disorders. Boston: Butterworth-Heinemann, 2002, pp. 433-444.

67. Logroscino G, Hesdorffer DC, Cascino G et al. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001; 42:1031-1035.

68. Rowan AJ, Ramsay RE, Collins JF et al. VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64:1868-1873.

69. O'Donovan D, Hausken T, Lei Y et al. Effect of aging on transpyloric flow, gastric emptying, and intragastric distribution in healthy humans - impact on glycemia. Dig Dis Sci 2005; 50:671-676.

70. Johnson EK, Jones JE, Seidenberg M et al. The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy. Epilepsia 2004; 45:544-550.

71. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005; 59:1435-1440.

72. Pisani F, Oteri G, Costa C et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25:91-110.

73. Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994; 16:382-385.

74. Babayigit A, Dirik E, Bober E et al. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006; 35:177-181.

75. Cannon KT, Choi MM, Zuniga MA. Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. Am J Geriatr Pharmacother 2006; 4:134-143.

76. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lam-otrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37:81-87.

77. Huying F, Klimpe S, Werhahn KJ. Antiepileptic drug use in nursing home residents: a cross-sectional, regional study. Seizure 2006; 15:194-197.

78. Cuadrado A, de las Cuevas I, Valdizan EM et al. Synergistic interaction between valproate and lam-otrigine against seizures induced by 4-aminopyridine and pentylenetetrazol in mice. Eur J Pharmacol 2002; 453:43-52.

79. Della Paschoa OE, Kruk MR, Hamstra R et al. Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure thresholds and pattern. Br J Pharmacol 1998; 125:997-1004.

80. Della Paschoa OE, Voskuyl RA, Danhof M. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. Br J Pharmacol 1998; 125:1610-1616.

81. Sorkin EM, Darvey DL. Review of Cimetidine drug interactions. Drug Intell Clin Pharm 1983; 17:110-120.

82. Suzuki Y, Nagai T, Mano T et al. Interaction between valproate formulation and phenytoin concentrations. Eur J Clin Pharmacol 1995; 48:61-63.

83. Crawford P. Interactions between antiepileptic drugs and hormaonal contraception. CNS Drugs 2002; 16:263-272.

84. Al-Windi A. Predictors of herbal medicine use in a Swedish health practice. Pharmacoepidemiol Drug Saf 2004; 13:489-496.

85. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 2005; 29:755-758.

86. Samuels N. Herbal remedies and anticoagulant therapy. Thromb Haemost 2005; 93:3-7.

87. Appendix 1. Interactions. http://bnf.org

88. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology 2006; 67:246-251.

89. Forsgren L, Beghi E, Oun A et al. The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurology 2005; 12:245-253.

90. Yankovsky AE, Andermann F, Bernasconi A. Characteristics of headache associated with intractable partial epilepsy. Epilepsia 2005; 46:1241-1245.

91. Kossoff EH, Hatfield LA, Ball KL et al. Comorbidity of epilepsy and headache in patients with Sturge-Weber syndrome. J Child Neurol 2005; 20:678-682.

92. Bussone G, Diener HC, Pfeil J et al. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005; 59:961-968.

93. Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41:119-128.

94. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalgia 1992; 12:81-84.

95. Lampl C, Katsarava Z, Diener HC et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76:1730-1732.

96. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; (3): CD003226.

97. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25:81-104.

98. Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65:111-118.

99. Magenta P, Arghetti S, Di Palma F et al. Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurol Sci 2005; 26:218-226.

100. Simpson DM, McArthur JC, Olney R et al; Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003; 60:1508-1514.

101. Guay DR. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geritr Pharmacolther 2003; 1:18-37.

102. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, doubleblind, placebo-controlled pilot study. Pain Med 2005; 6:225-234.

103. Thienel U, Neto W, Schwabe SK et al; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004; 110:221-231.

104. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005; 4:465-475.

105. Vignatelli L, Billiard M, Clarenbach P et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13:1049-1065.

106. Telstad W, Sorensen O, Larsen S et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984; 288:444-446.

107. Eisensehr I, Ehrenberg BL, Rogge Solti S et al. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004; 251:579-588.

108. Ettinger AB, Reed ML, Goldberg JF et al. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 2005; 65:535-540.

109. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005; 59:1435-1440.

110. Edwards KR, Sackellares JC, Vuong A et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001; 2:28-36.

111. Chouinard MJ, Nguyen DK, Clement JF et al. Catatonia induced by levetiracetam. Epilepsy Behav 2006; 8:303-307.

112. Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: A comparative short-term study. Epilepsy Behav 2006; 9:424-431.

113. Salpekar JA, Conry JA, Doss W et al. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav 2006; 9:327-334.

Was this article helpful?

0 0
Naturally Cure Your Headaches

Naturally Cure Your Headaches

Are Headaches Taking Your Life Hostage and Preventing You From Living to Your Fullest Potential? Are you tired of being given the run around by doctors who tell you that your headaches or migraines are psychological or that they have no cause that can be treated? Are you sick of calling in sick because you woke up with a headache so bad that you can barely think or see straight?

Get My Free Ebook


Post a comment